Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet
The consensus price target hints at a 67.1% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of Clinical Oncology annual meeting. Called ivonescimab, the bispecific antibody targets PD-1 — similar to Merck's best-selling drug Keytruda — and VEGF — similar to Roche's Avastin.
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
Summit Therapeutics posts a wider Q4 loss as R&D spending surges. Its ivonescimab pipeline advances with a BLA filing and multiple late-stage cancer trials underway.
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug
Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript
Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Summit C-Suite Risks Success, Akeso Wins Either Way
Akeso stands out as a diversified Chinese biotech with strong licensing deals, a robust pipeline, and growing revenues from multiple approved therapies. Unlike SMMT, AKESF benefits from milestone payments, retains Chinese commercialization rights, and faces less development risk from single-asset dependence. SMMT's commercialization ability is questionable, with leadership concerns, cash burn, and the loss of key partnerships like Pfizer undermining its prospects.
